Clinical Trial Update: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival [Phase 2]

View source ↗

Summary

A Phase 2 study of erlotinib (Tarceva) in combination with gemcitabine in unresectable or metastatic pancreatic cancer evaluates whether treatment-induced skin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-10-15